Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-Y617F mutations

Blood

Volumn 111, Issue 7, 2008, Pages 3863-3866

  Li, Sai ^a   Kralovics, Robert ^b   De Libero, Gennaro ^a   Theocharides, Alexandre ^a   Gisslinger, Heinz ^b   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ALLELE; ARTICLE; CELL LINEAGE; CHROMOSOME 9P; ERYTHROID CELL; EXON; GENE MUTATION; GENETIC HETEROGENEITY; GRANULOCYTE; HOMOZYGOSITY; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOID CELL; MITOSIS; MONOCYTE; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; THROMBOCYTE; AMINO ACID SUBSTITUTION; BLOOD; CLINICAL TRIAL; CLONOGENIC ASSAY; ERYTHROID PRECURSOR CELL; FEMALE; GENETICS; LEUKOCYTE; MALE; METABOLISM; MISSENSE MUTATION; MULTICENTER STUDY; PATHOLOGY;

ALLELES; AMINO ACID SUBSTITUTION; COLONY-FORMING UNITS ASSAY; ERYTHROID PROGENITOR CELLS; EXONS; FEMALE; HUMANS; JANUS KINASE 2; LEUKOCYTES; MALE; MUTATION, MISSENSE; POLYCYTHEMIA VERA;

EID: 43549105688     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-111971     Document Type: Article

References (28)

1. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
2. James C, Ugo V, Le Gouedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005:365: 1054-1061.
4. Levine RL, Wadleigh M, Gools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005:7:387-397.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
6. Zhao R, Xing S, Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
7. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006; 103:6224-6229.
8. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108:3128-3134.
9. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109:71-77.
10. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136:745-751.
11. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007;21:2206-2207.
12. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686-1689.
13. Vardiman JW, Harris NL Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.
14. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrornbocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
15. Kralovics R. Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003; 102:1869-1871.
16. De Libera G. Methods for the generation of T cell clones and epithelial cell lines from excised human biopsies or needle aspirates. In: Fernandez N, ed. MHC: A Practical Approach, Oxford, United Kingdom, Oxford University Press, 1997:123-140.
17. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
18. Prchal JT, Guan YL, Prchal JF, Barany F. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis [letter]. Blood. 1993;81:269-271.
19. Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol. 2005;12:112-116.
20. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131: 320-328.
21. Pardanani A, Lasho TL. Finke C, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007;25:2358-2362.
22. Butcher CM, Hutton JF, Hahn U, et al. Cellular origin and lineage specificity of the JAK2(V617F) allele in polycythemia vera. Blood. 2007:109:386-387.
23. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
24. Dupont S. Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021.
25. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrornbocythemia. Blood. 2006: 108:2435-2437.
26. Percy MJ, Scott LM, Erber WN, et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica. 2007;92:1607-1613.
27. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
28. Lasho TL, Pardanani A, McClure RF, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden overtime. Br J Haematol. 2006;135:683-687.